NEW DELHI: Clinical trials for the Covid-19 candidate vaccine developed by the University of Oxford, which were expected to begin at the Postgraduate Institute of Medical Education and Research (PGIMER) in Chandigarh, have been delayed for at least a week.
Trials that were expected to begin in the first week of September have been delayed due to pending safety approval from the Data Security and Monitoring Board (DSMB) for the first 100 candidates selected to undergo the trials, the institute said. to IANS.
Consequently, the recruitment of candidates for trials has been suspended.
“At the moment, further recruitment of candidates for Oxford vaccine trials is on hold because we are awaiting safety approval of the first 100 participants recruited so far by the Data Safety and Monitoring Board, we could tell you about it. any developments on this front only next weekend, “said Prof. Dr. Madhu Gupta, the principal investigator of the vaccine trial scheduled at PGIMER.
The main institute said it received 400 volunteers for the trials. Of these, 253 would be given the first dose of the subtest vaccine.
Gupta had previously reported that 16-member staff, including herself, would oversee clinical trials.
PGIMER is among the 17 sites selected for human clinical trials of the adenovirus-based Covid-19 candidate vaccine, jointly developed by AstraZeneca and the University of Oxford.
The institute will participate in the second and third phases of the proposed vaccine. The production and marketing of the vaccine will be in charge of the Serum Institute of India (SII), one of the largest vaccine producers in the country.
Adar Poonawalla, chief executive of the Pune-based firm, had said that the coronavirus vaccine could be ready by the end of this year.
Trials that were expected to begin in the first week of September have been delayed due to pending safety approval from the Data Security and Monitoring Board (DSMB) for the first 100 candidates selected to undergo the trials, the institute said. to IANS.
Consequently, the recruitment of candidates for trials has been suspended.
“At the moment, further recruitment of candidates for Oxford vaccine trials is on hold because we are awaiting safety approval of the first 100 participants recruited so far by the Data Safety and Monitoring Board, we could tell you about it. any developments on this front only next weekend, “said Prof. Dr. Madhu Gupta, the principal investigator of the vaccine trial scheduled at PGIMER.
The main institute said it received 400 volunteers for the trials. Of these, 253 would be given the first dose of the subtest vaccine.
Gupta had previously reported that 16-member staff, including herself, would oversee clinical trials.
PGIMER is among the 17 sites selected for human clinical trials of the adenovirus-based Covid-19 candidate vaccine, jointly developed by AstraZeneca and the University of Oxford.
The institute will participate in the second and third phases of the proposed vaccine. The production and marketing of the vaccine will be in charge of the Serum Institute of India (SII), one of the largest vaccine producers in the country.
Adar Poonawalla, chief executive of the Pune-based firm, had said that the coronavirus vaccine could be ready by the end of this year.
.
